Skip to search formSkip to main contentSkip to account menu

icosapent ethyl 500 MG Oral Capsule [Vascepa]

Known as: Vascepa 0.5 GM Oral Capsule, Vascepa 500 MG Oral Capsule 
National Institutes of Health

Related topics

Related topics

10 relations
Eicosapentaenoic AcidGelatinGlycerinOral Capsule

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients
ABSTRACT Objectives: Residual cardiovascular risk and persistently elevated triglycerides (TGs) may remain despite statin therapy… 
2016
2016
Icosapent ethyl in hypertriglyceridaemia: a guide to its use
Icosapent ethyl (Vascepa®) is a high-purity ethyl ester of eicosapentaenoic acid (EPA), a long-chain omega-3 fatty acid… 
2015
2015
Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides
Abstract In patients with dyslipidemia, elevated triglyceride (TG) levels, or TG-rich lipoproteins, and cardiovascular risk may… 
Review
2014
Review
2014
Icosapent Ethyl: A Review of Its Use in Severe Hypertriglyceridemia
Icosapent ethyl (Vascepa®) is a high-purity ethyl ester of eicosapentaenoic acid (EPA) that is de-esterified to EPA following… 
2013
2013
AFFIRM and Vascepa
  • 2013
  • Corpus ID: 26388326
Volume 28 Issue 7 April 2013 1 trial fibrillation (AF) is a supraventricular tachyarrhythmia characterized by uncoordinated… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)